Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Rhea-AI Summary

Invivyd (Nasdaq: IVVD), a biopharmaceutical company specializing in protection against serious viral infectious diseases, announced that Marc Elia, Chairman of Invivyd's Board, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The presentation is scheduled for Monday, May 20, 2024, at 3:00 p.m. ET in New York, NY. Alongside the fireside chat, Invivyd's management team will hold investor meetings. Interested investors can contact their H.C. Wainwright representative for meeting arrangements. The fireside chat will be webcast live on Invivyd's investor relations website and archived for 30 days.

Positive

• Marc Elia, Chairman of Invivyd's Board, will present at a high-profile investor conference, increasing visibility.
• Potential for new investor interest and engagements through scheduled investor meetings.
• Webcast availability extends the reach of the presentation beyond the conference attendees.

Negative

• No new financial or clinical data disclosed in the announcement.
• The short-term impact on stock performance is uncertain without substantial new information.

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is scheduled to present in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 3:00 p.m. ET in New York, NY.

In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their H.C. Wainwright representative.

A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the presentation.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-0160
investors@invivyd.com

FAQ

When will Invivyd present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

Marc Elia, Chairman of Invivyd's Board, will present on Monday, May 20, 2024, at 3:00 p.m. ET.

What will Marc Elia discuss at the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

Marc Elia will participate in a fireside chat, discussing Invivyd's business and strategies.

How can investors attend Invivyd's fireside chat at the BioConnect Investor Conference?

Investors can watch the live webcast on Invivyd's investor relations website or meet the management team by contacting their H.C. Wainwright representative.

How long will the webcast of Invivyd's presentation be available?

The webcast will be archived and available on Invivyd's investor relations website for approximately 30 days.